CRMD

CorMedix Inc.

Healthcare
Biotechnology
$614M market cap

Forecast run · Sep 14, 2026Upside rank 1577 of 3,136

Model Signal

ForecastQ Daily Probabilities

33.7%

30.3%

14.1%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$7.83

Price target$14.00

Implied move+78.9%

Analysts8

ForecastQ Portfolios

CRMD is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.